Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers. » Read More
By: Dan Mangan
UnitedHealth denies allegations it gamed the nation's Medicare system for hundreds of millions of dollars. » Read More
By: Bertha Coombs
House Speaker Paul Ryan said they plan to introduce legislation as early as next Tuesday. » Read More
Obamacare repeal and failed insurance mergers have been dominating health-care headlines, but some surprise stock winners may emerge.
Spending on health nationally grew by an estimated 4.8 percent in 2016, but is expected to rise at a quicker pace through 2025.
This is occurring even as the Trump administration issues new rules to try to stabilize the Obamacare exchanges.
Tax filers remain responsible for paying a penalty if they fail to have health insurance coverage or an exemption from that mandate.
The company reported a fourth-quarter loss of $2.96 per share after the company took a $5.6 billion charge.
Open enrollment would run from November through Dec. 15, and states would have control over the size of an insurance plan's network.
Talk that China's insurance regulator Xiang Junbo may be under investigation is raising eyebrows, the SCMP reports.
In the wake of Humana's comment, President Donald Trump tweeted that the insurer's decision was another example of Obamacare's failure.
American International Group (AIG), the largest commercial insurer in the United States and Canada, reported a bigger quarterly loss than last year.
Just 8.8 percent of Americans lack health coverage as Republicans move to repeal key parts of the Affordable Care Act.
Health insurer Aetna and rival Humana say they have mutually ended their $34 billion merger agreement.
Michael Barakos of J.P. Morgan Asset Management explains why he favors European bank stocks.
The key to boosting Japan’s sluggish economy isn’t more monetary policy, it’s making households feel secure, a former BOJ board member said.
Brian Benari, CEO of Challenger Financial Group, talks about the company's earnings and its strategy involving partnerships.
Marathon says it will charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.
Warwick Aubin of VisionFund Australia talks about how the organization has made an impact on over 4.4 million children through microfinance.
Get the best of CNBC in your inbox